Global Public Health Portfolio
The World Health Organization, Coalition for Epidemic Preparedness, and the National Institute of Allergy and Infectious Diseases of the United States National Institute of Health have published lists of their priority pathogens, including emerging threats and neglected diseases.
The mRNA Access program will offer researchers use of Moderna’s mRNA technology to target these identified priority pathogens to accelerate the development of medicines to prevent these diseases.
Interested in mRNA Access?
Partner with us to bring this global health initiative to life.